Skip to main content
BIO-RAD LABORATORIES, INC. logo

BIO-RAD LABORATORIES, INC. — Investor Relations & Filings

Ticker · BIO ISIN · US0905721082 LEI · 549300ZC1GPV35XYDK53 US Manufacturing
Open in API
Filings indexed 1,485 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country US United States of America
Listing US BIO

About BIO-RAD LABORATORIES, INC.

https://www.bio-rad.com/

Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets. The company's portfolio includes instruments, software, consumables, reagents, and quality control systems. These products are utilized by researchers, clinicians, and laboratories to separate, identify, and analyze biological materials. Key applications include advancing scientific discovery in areas such as genomics and proteomics, as well as supporting disease detection, diagnosis, and monitoring. The company also serves the food science market with safety and quality testing solutions.

Recent filings

Filing Released Lang Actions
SD - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form SD (“Specialized Disclosure Report”) filed with the SEC under Rule 13p-1 regarding conflict minerals. It is a regulatory compliance filing rather than a full financial report, earnings release, or ESG/sustainability report. It doesn’t fit any of the more specific categories (10-K, IR, SR, etc.), so per the fallback rule it should be classified as a Regulatory Filing (RNS).
2026-05-13 English
S-8
Share Issue/Capital Change Classification · 90% confidence The document is a Form S-8 registration statement filed with the SEC to register 800,000 additional shares of Class A Common Stock under Bio-Rad’s 2017 Incentive Award Plan. Form S-8 specifically registers new shares for issuance under an employee benefit plan—this constitutes a capital change/event. Therefore it fits the “Share Issue/Capital Change” category (SHA) rather than a financial report or earnings release. It is not merely an announcement of a report (RPA) nor a proxy/management discussion. Accordingly, the correct classification is SHA.
2026-04-30 English
10-Q
Interim / Quarterly Report Q1 2026
2026-04-30 English
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 30, 2026, reporting the company's financial results for the quarter ended March 31, 2026. It includes a press release and a supplemental earnings presentation as exhibits. The document explicitly states it is a Current Report pursuant to the Securities Exchange Act of 1934, and the content focuses on announcing quarterly financial results and related supplemental materials. The document length is 4394 characters, which is relatively short and primarily serves as an announcement of earnings results and supplemental presentation rather than containing detailed financial statements or analysis itself. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. The presence of a press release and supplemental presentation attached as exhibits further supports this classification. Therefore, the document is best classified as an Earnings Release (ER).
2026-04-30 English
8-K
Regulatory Filings
2026-04-24 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-03-26 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.